N. Matsukuma

发表

First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study

T. Kawaguchi, H. Koga, T. Torimura, 2021, Cancer medicine.

Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma

K. Ueshima, H. Koga, T. Ueno, 2021, Cancers.

Transmission routes and clinical courses in sporadic acute hepatitis C

M. Sata, M. Kojiro, M. Kage, 1997, Journal of viral hepatitis.

A CASE REPORT OF MUCINOUS ADENOCARCINOMA OF THE RESIDUAL APPENDIX WITH FISTULA FORMATION FOLLOWING APPENDECTOMY

K. Shirouzu, K. Tanikawa, K. Mitsuyama, 1989 .

A pilot study of natural interferon γ therapy for chronic hepatitis C

K. Tanikawa, T. Ide, M. Sata, 1997 .

Efficacy, Safety, and Survival Factors for Sorafenib Treatment in Japanese Patients with Advanced Hepatocellular Carcinoma

H. Koga, M. Sata, T. Torimura, 2012, Oncology.

Functional liver imaging with asialoglycoprotein receptors and serum hyaluronate in a patient with amyloidosis

K. Tanikawa, M. Harada, T. Ueno, 1995, Journal of Gastroenterology.

EARLY CARCINOMA OF THE RECTUM DEVELOPING DURING THE COURSE OF ULCERATIVE COLITIS; REPORT OF A CASE

M. Morimatsu, K. Tanikawa, A. Toyonaga, 1987 .